## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract, with no access to full methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report a computational screening of a compound library to identify small molecule inhibitors of MBD2, a methylated DNA binding protein. They performed docking against the methylated DNA binding domain, validated results with molecular dynamics simulation and per residue energy decomposition, and assessed drug likeness via ADMET prediction. Two compounds, CID3100583 and 8,8 ethylenebistheophylline, are proposed as novel candidates that may disrupt MBD2 DNA interaction, with potential applications in cancer treatment and somatic cell reprogramming.
- **Visible evidence base** Abstract text only. No figures, tables, methods details, or numerical results are provided.
- **Missing materials affecting confidence** Full manuscript, docking scores, MD simulation parameters and trajectories, per residue energy decomposition data, ADMET results, compound structures, and any comparison with known inhibitors or experimental validation.

## Reviewer
- **Overall assessment** The abstract presents a straightforward computational pipeline for identifying MBD2 inhibitors. The workflow is logical and the topic is of interest given the limited availability of MBD2 inhibitors. However, the abstract provides insufficient quantitative detail to assess the robustness of the findings. The claim that two compounds are "prospective inhibitors" is not supported by experimental validation, and the computational evidence as described is too sparse to establish functional relevance. The work may be of interest to computational chemists and epigenetic researchers, but the current evidence base is insufficient to support the broad conclusions.
- **Who would be interested in the results, and why** Computational drug discovery researchers interested in epigenetic targets, medicinal chemists seeking lead compounds for MBD2, and cancer biologists studying DNA methylation pathways. The proposed compounds could serve as starting points for further optimization, though this requires experimental confirmation.
- **Major strengths** The study addresses a relevant and under explored target. The use of multiple computational methods (docking, MD simulation, energy decomposition, ADMET) is appropriate for a preliminary screening study. The focus on druggable pockets and off target prediction is commendable.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The absence of quantitative docking scores, MD stability metrics, and ADMET parameters prevents verification of the claims. No experimental or literature based validation is provided to confirm that the compounds actually inhibit MBD2 function. The abstract does not specify the size or diversity of the screened library, nor the criteria for selecting "promising molecules."
- **Assessment against Nature-style criteria** Originality is moderate, as computational screening for MBD2 inhibitors is not entirely novel but the specific compounds are new. Scientific importance is potentially high given MBD2's role in cancer and reprogramming, but the evidence is preliminary. Interdisciplinary readership is plausible, though the abstract is too technical for nonspecialists without context. Technical soundness cannot be fully assessed from the abstract alone, but the described methods are standard. Readability for nonspecialists is limited due to jargon and lack of explanatory context.
- **Recommendation posture** Currently not established from the provided evidence. The computational findings are suggestive but require substantial additional data and experimental validation to support the claims.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The abstract claims that "reasonable binding energies and docking residues" were detected, and that two compounds are "novel candidates" as MBD2 inhibitors.
- **Evidence pointer** Abstract text, location not provided
- **Concern** No numerical data are provided for docking scores, binding energies, or specific residues. The term "reasonable" is subjective and cannot be evaluated. The selection of the two final compounds is not justified with quantitative criteria.
- **Why it matters** Without quantitative results, the reader cannot assess whether the binding is specific or merely a computational artifact. The claim of "novel candidates" requires evidence that the compounds bind with meaningful affinity and selectivity.
- **Resolution test** Provide docking scores (e.g., binding free energies), comparison with known binders or decoys, and a clear threshold for selection. Include per residue decomposition data to show key interactions.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Validation
- **Claim pointer** The abstract states that docking results were "validated via MD simulation and per residue energy decomposition calculation."
- **Evidence pointer** Abstract text, location not provided
- **Concern** MD simulation and energy decomposition are computational validations, not experimental ones. They confirm stability of the docked pose but do not prove biological activity. The abstract does not report MD simulation duration, convergence criteria, or stability metrics (e.g., RMSD, RMSF).
- **Why it matters** The term "validated" is misleading if it refers only to computational consistency. Without experimental data (e.g., binding assays, cellular activity), the claim that these compounds are "prospective inhibitors" is unsupported.
- **Resolution test** Clarify that validation is computational only. Provide MD simulation details and stability metrics. If possible, include experimental binding or functional data, or clearly state that such data are not yet available.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim scope
- **Claim pointer** The abstract concludes that the compounds "have been considered prospective inhibitors with the usage potential in a wide range of applications from cancer treatment to somatic cell reprogramming protocols."
- **Evidence pointer** Abstract text, location not provided
- **Concern** This conclusion extends far beyond the computational evidence. No in vitro or in vivo data are presented, and the therapeutic implications are speculative. The abstract does not discuss potential off target effects or specificity of the compounds for MBD2 over other MBD family members.
- **Why it matters** Overstating implications can mislead readers and is not consistent with the level of evidence. The claim of broad applicability is not justified by the described work.
- **Resolution test** Restrict conclusions to the computational identification of candidates. Discuss limitations and the need for experimental validation. Avoid therapeutic claims unless supported by data.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Compound names
- **Evidence pointer** Abstract text, location not provided
- **Issue** The compound "8,8 ethylenebistheophylline" is not a standard chemical name and may be confusing. The identifier "CID3100583" is a PubChem CID, but the source of the other compound is unclear.
- **Required correction** Provide full chemical names, structures, or database identifiers for both compounds to ensure reproducibility.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Methodology transparency
- **Affected element** Library description
- **Evidence pointer** Abstract text, location not provided
- **Issue** The abstract mentions a "comprehensive compound library" but does not specify its size, source, or diversity. This limits the reader's ability to judge the screening scope.
- **Required correction** State the library name, number of compounds, and any filtering criteria used before docking.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Terminology
- **Affected element** "Druggable pockets"
- **Evidence pointer** Abstract text, location not provided
- **Issue** The term "druggable pockets" is used without definition or evidence. It is unclear how druggability was assessed.
- **Required correction** Define the criteria for druggability or replace with a more neutral term such as "putative binding sites."

## Risk / unsupported claims
- The claim that the two compounds are "prospective inhibitors" is unsupported without experimental validation.
- The statement that the compounds have "usage potential in a wide range of applications" is speculative and not backed by data.
- The term "validated" for MD simulation and energy decomposition is misleading, as these are computational consistency checks, not biological validation.
- The abstract implies a comprehensive screening, but the library size and selection criteria are not provided, making the scope unverifiable.